49 results on '"Schechter, Meir"'
Search Results
2. Post hoc analysis of the SONAR trial indicates that the endothelin receptor antagonist atrasentan is associated with less pain in patients with type 2 diabetes and chronic kidney disease
3. Effects of dapagliflozin on hospitalisations in people with type 2 diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial
4. Long-Term, Real-World Kidney Outcomes with SGLT2i versus DPP4i in Type 2 Diabetes without Cardiovascular or Kidney Disease
5. The effect of lifestyle intervention on cardiometabolic risk factors in mental health rehabilitation hostel residents at-risk: a cluster-randomized controlled 15-month trial
6. Epidemiology of the diabetes-cardio-renal spectrum: a cross-sectional report of 1.4 million adults
7. Normoalbuminuria—is it normal? The association of urinary albumin within the 'normoalbuminuric' range with adverse cardiovascular and mortality outcomes: A systematic review and meta‐analysis.
8. Normo-albuminuria- Is it normal? The association of urinary albumin within the "normoalbuminuric" range with adverse cardiovascular and mortality outcomes: a systematic review and meta-analysis. (Embase).
9. Normo-albuminuria- Is it normal? The association of urinary albumin within the "normoalbuminuric" range with adverse cardiovascular and mortality outcomes: a systematic review and meta-analysis. (PubMed).
10. Abstract 10006: The Effect of Dapagliflozin on Hospital Admissions in Patients With Type 2 Diabetes: Post Hoc Analysis of the DECLARE-TIMI 58 Trial
11. Kidney Outcomes With Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes
12. Efficacy and Safety of Dapagliflozin in Patients with Chronic Kidney Disease across the Spectrum of Frailty
13. α-Synuclein Translocates to the Nucleus to Activate Retinoic-Acid-Dependent Gene Transcription
14. Cardiorenal outcomes with sodium/glucose cotransporter-2 inhibitors in patients with type 2 diabetes and low kidney risk: real world evidence
15. From glucose lowering agents to disease/diabetes modifying drugs: a “SIMPLE” approach for the treatment of type 2 diabetes
16. Efficacy and Safety of Dapagliflozin in Patients With Chronic Kidney Disease Across the Spectrum of Frailty
17. Effects of Dapagliflozin on Hospitalizations in Patients With Chronic Kidney Disease
18. Risk of hospitalization with sodium‐glucose cotransporter‐2 inhibitors versus dipeptidyl peptidase‐4 inhibitors in patients with type 2 diabetes lacking evidence of chronic kidney disease: Real‐world data
19. Dapagliflozin and Anemia in Patients with Chronic Kidney Disease
20. A role for α-Synuclein in axon growth and its implications in corticostriatal glutamatergic plasticity in Parkinson’s disease
21. Effects of Dapagliflozin on Hospitalizations in Patients With Chronic Kidney Disease:A Post Hoc Analysis of DAPA-CKD
22. Dapagliflozin and Anemia in Patients with Chronic Kidney Disease
23. Medical cannabis for pain management in patients undergoing chronic hemodialysis: randomized, double-blind, cross-over, feasibility study
24. Interleukin-6 and Cardiovascular and Kidney Outcomes in Patients with Type 2 Diabetes: New Insights from CANVAS
25. Dapagliflozin and prevention of kidney disease among patients with type 2 diabetes– post hoc analyses from the DECLARE-TIMI 58 trial
26. 862-P: Interleukin-6 and Cardiovascular Outcomes in Patients with Type 2 Diabetes: A Post Hoc Analysis of CANVAS Trial
27. 867-P: Favorable Kidney Outcomes Are Associated with Empagliflozin vs. DPP4i in Patients with Diabetes and Normal Kidney Function Real-World Evidence
28. Medical cannabis for pain management in patients undergoing chronic hemodialysis: randomized, double-blind, cross-over, feasibility study.
29. Prediction of the Effects of Liraglutide on Kidney and Cardiovascular Outcomes Based on Short-Term Changes in Multiple Risk Markers
30. Preventing all‐cause hospitalizations in type 2 diabetes with sodium‐glucose cotransporter‐2 inhibitors and glucagon‐like peptide‐1 receptor agonists: A narrative review and proposed clinical approach
31. Additional file 1 of Epidemiology of the diabetes-cardio-renal spectrum: a cross-sectional report of 1.4 million adults
32. Loss of Corticostriatal Mu-Opioid Receptors in α-Synuclein Transgenic Mouse Brains
33. Interleukin-6 and Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: New Insights From CANVAS.
34. An Emerging Role for Phosphoinositides in the Pathophysiology of Parkinson’s Disease
35. The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58
36. Dapagliflozin and Prevention of Kidney Disease Among Patients With Type 2 Diabetes: Post Hoc Analyses From the DECLARE-TIMI 58 Trial.
37. Adolescent Thyroid Disorders and Risk for Type 2 Diabetes in Young Adulthood
38. Coping with Fear of Hypoglycemia Using a Smartphone Application Combining Biofeedback and Virtual Reality
39. Additional file 2 of A role for α-Synuclein in axon growth and its implications in corticostriatal glutamatergic plasticity in Parkinson’s disease
40. Paving the way to precision medicine for diabetic kidney disease: the PRIORITY trial
41. α-Synuclein facilitates endocytosis by elevating the steady-state levels of phosphatidylinositol 4,5-bisphosphate
42. α-Synuclein Translocates to the Nucleus to Activate Retinoic Acid-Dependent Gene Transcription
43. α-Synuclein facilitates endocytosis by elevating the steadystate levels of phosphatidylinositol 4,5-bisphosphate.
44. Associations Between Albuminuria and Clinical Outcomes in Patients with CKD with and Without Diabetes: New Insights from DAPA-CKD
45. Mediators of the Kidney Protective Effects of Dapagliflozin in Patients with CKD with or Without Type 2 Diabetes
46. Total and Proteinase K-Resistant α-Synuclein Levels in Erythrocytes, Determined by their Ability to Bind Phospholipids, Associate with Parkinson’s Disease
47. Efficacy and Safety of Dapagliflozin in Patients With Chronic Kidney Disease Across the Spectrum of Frailty.
48. Medical cannabis for pain management in patients undergoing chronic hemodialysis: randomized, double-blind, cross-over, feasibility study.
49. [IMPROVEMENT OF RENAL OUTCOMES WITH SODIUM-GLUCOSE COTRANSPORTER-2 (SGLT2) INHIBITORS].
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.